Credelio Plus

RSS

lotilaner / milbemycin oxime

Authorised
This medicine is authorised for use in the European Union.

Overview

Credelio Plus is a veterinary medicine used in dogs to treat concurrent infestations with parasites living outside (ticks and/or fleas) and inside (worms) the animal's body. The medicine can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).

Credelio Plus contains the active substances lotilaner and milbemycin oxime.

This EPAR was last updated on 04/08/2021

Authorisation details

Product details
Name
Credelio Plus
Agency product number
EMEA/V/C/005325
Active substance
  • lotilaner
  • milbemycin oxime
International non-proprietary name (INN) or common name
lotilaner / milbemycin oxime
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP54AB51
Publication details
Marketing-authorisation holder
Elanco GmbH
Date of issue of marketing authorisation valid throughout the European Union
14/04/2021
Contact address

Heinz-Lohmann-Str 4
27472 Cuxhaven
Germany

Product information

14/04/2021 Credelio Plus - EMEA/V/C/005325 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Endectocides

Therapeutic indication

For use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

Assessment history

How useful was this page?

Add your rating